Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran
Completed · Phase 1 · Has a placebo group
Conditions studied: Nausea
In brief
This is a Phase 1, randomized study to evaluate the rate of nausea in healthy premenopausal study participants following a single dose of BMT with or without a single 8 mg po dose of Zofran given 30 minutes before BMT dosing.
Key facts
- Study ID
- NCT03973047
- Run by
- AMAG Pharmaceuticals, Inc.
- People needed
- 228
- Starts
- 2019-06-17
- Expected to finish
- 2019-07-20
- Last updated by the study team
- 2022-04-04
Who can join
Age: 18 and older, up to 55. Sex: female. Healthy volunteers: accepted.
Where it is running
- ICON Early Phase Serrvices, LLC — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.